- Home
- JCI vs TAK Comparison
JCI vs TAK Comparison
Compare JCI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCI
- TAK
- Stock Information
- Founded
- JCI 1885
- TAK 1781
- Country
- JCI Ireland
- TAK Japan
- Employees
- JCI N/A
- TAK N/A
- Industry
- JCI Industrial Machinery/Components
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- JCI Industrials
- TAK Health Care
- Exchange
- JCI Nasdaq
- TAK Nasdaq
- Market Cap
- JCI 49.1B
- TAK 47.0B
- IPO Year
- JCI N/A
- TAK N/A
- Fundamental
- Price
- JCI $91.24
- TAK $14.29
- Analyst Decision
- JCI Buy
- TAK
- Analyst Count
- JCI 13
- TAK 0
- Target Price
- JCI $91.46
- TAK N/A
- AVG Volume (30 Days)
- JCI 4.4M
- TAK 1.9M
- Earning Date
- JCI 05-07-2025
- TAK 05-08-2025
- Dividend Yield
- JCI 1.65%
- TAK 4.11%
- EPS Growth
- JCI 45.88
- TAK 15.39
- EPS
- JCI 3.62
- TAK 0.83
- Revenue
- JCI $23,248,000,000.00
- TAK $29,124,927,177.00
- Revenue This Year
- JCI $2.86
- TAK $8.66
- Revenue Next Year
- JCI $4.65
- TAK N/A
- P/E Ratio
- JCI $24.77
- TAK $34.09
- Revenue Growth
- JCI 8.21
- TAK 9.83
- 52 Week Low
- JCI $64.31
- TAK $12.58
- 52 Week High
- JCI $92.41
- TAK $15.37
- Technical
- Relative Strength Index (RSI)
- JCI 71.13
- TAK 38.68
- Support Level
- JCI $87.77
- TAK $15.01
- Resistance Level
- JCI $89.49
- TAK $15.43
- Average True Range (ATR)
- JCI 2.20
- TAK 0.19
- MACD
- JCI 1.32
- TAK -0.05
- Stochastic Oscillator
- JCI 93.80
- TAK 6.17
About JCI Johnson Controls International plc
Johnson Controls manufactures, installs, and services commercial HVAC systems, building management platforms and controls, fire and security solutions, and industrial refrigeration units. Commercial HVAC and fire and security each account for approximately 45% of sales, while industrial refrigeration and other solutions account for the remaining 10% of revenue. In fiscal 2024, Johnson Controls generated nearly $23 billion in pro forma revenue.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.